Technivie, Viekirax (paritaprevir) is a small molecule pharmaceutical. Paritaprevir was first approved as Technivie on 2015-01-14. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Viekira pak's patents are valid until 2032-04-13 (FDA).
|Indication||chronic hepatitis c, hepatitis c|
|Drug Class||Antivirals: serine protease inhibitors|